SMAD3 and pulmonary fibrosis: Subsequent Shenks treatment led to a lower phosphorylation level of Smad3 (40.0% lower, P < 0.001), indicating that Shenks treatment alleviated the abnormal activation of the TGF-β pathway in pulmonary fibrosis.